This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript)

Avanir Pharmaceuticals, Inc. (AVNR)

Bank of America Merrill Lynch Health Care Conference

May 17, 2012 01:00 PM ET


Keith Katkin - CEO

Greg Flesher - CBO



Unidentified Analyst

(inaudible) one of the biotech analysts here at Bank of America Merrill Lynch. It's my pleasure to introduce Avanir Pharmaceuticals who's got Keith Katkin, CEO to give us the latest presentation.

Keith Katkin

Thanks Rachel and good morning everyone. Thank you for joining us for the Avanir corporate presentation. I'm joined here today with Dr. Ian Clements, our Head of Investor Relations and Greg Flesher, our Chief Business Officer. I'd like to start with our forward looking statement as I will be making statements that are forward looking in nature. We encourage everyone to look at our publicly available documents either on the Avanir website or on the SEC's website.

Avanir is a specialty biopharmaceutical company focused on CNS therapies and our lead product, NUEDEXTA launched a little over a year ago and has met with very nice market acceptance and growth over the past year as the first and only FDA approved product for the treatment of pseudobulbar affect or PBA. Pseudobulbar affect is a very large market with a high unmet medical need and now that we have a marketed product we start to look to develop NUEDEXTA for other potential indications and if you look at NUEDEXTA from a mechanistic perspective, it is an NMDA receptor antagonist and a sigma-1 agonist and because of that mechanism there is a potential for numerous follow on indications, some of which are listed here on this slide and currently are soon to be under developed by Avanir.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs